Comparative Pharmacology
Head-to-head clinical analysis: METATENSIN 2 versus REGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METATENSIN 2 versus REGROTON.
METATENSIN #2 vs REGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
None Documented
None Documented
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination